Monte Rosa Therapeutics, Inc. (GLUE): Operating Income

Annual figures by period end, from SEC filings.

-$54.21M

Year ended 2025-12-31

-$181.85M

Trailing 12 months to 2026-06-30

2020-12-31 Operating Income (USD) 2025-12-31

Period ended	Operating Income	Change YoY	Source filing
2025-12-31	-$54.21M	n/m	2026-03-17, From 2025-01-01
2024-12-31	-$81.11M	n/m	2026-03-17, From 2024-01-01
2023-12-31	-$143.31M	n/m	2025-03-20, From 2023-01-01
2022-12-31	-$112.38M	n/m	2024-03-14, From 2022-01-01
2021-12-31	-$72.88M	n/m	2023-03-16, From 2021-01-01
2020-12-31	-$28.01M	n/a	2022-03-29, From 2020-01-01

Operating Income at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Operating Income	Change YoY
Monte Rosa Therapeutics, Inc. (GLUE)	2025-12-31	-$54.21M	n/m
Atara Biotherapeutics, Inc. (ATRA)	2025-12-31	$35.86M	n/m
Agenus Inc (AGEN)	2025-12-31	-$20.17M	n/m
ImmunityBio, Inc. (IBRX)	2025-12-31	-$256.03M	n/m
Beam Therapeutics Inc. (BEAM)	2025-12-31	-$383.69M	n/m
Century Therapeutics, Inc. (IPSC)	2025-12-31	-$17.27M	n/m
Sutro Biopharma, Inc. (STRO)	2025-12-31	-$158.37M	n/m
Ginkgo Bioworks Holdings, Inc. (DNA)	2025-12-31	-$315.28M	n/m
REGENXBIO Inc. (RGNX)	2025-12-31	-$161.20M	n/m

Compare GLUE, ATRA, AGEN, IBRX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗